Opioid receptors: Distinct roles in mood disorders

Trends in Neurosciences

Volumn 36, Issue 3, 2013, Pages 195-206

  Lutz, Pierre Eric ^a,b,c   Kieffer, Brigitte L ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Delta opioid receptor; Depression; Kappa opioid receptor; Mood; Mu opioid receptor

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANTIDEPRESSANT AGENT; BW 363U8; CODEINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN 2; DYNORPHIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; KNT 127; LEVORPHANOL; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N [2 BENZYL 3 [(HYDROXYAMINO)CARBONYL]PROPIONYL]PHENYLALANINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NIH 11082; OPIORPHIN; PREPROENKEPHALIN; RB 38B; SNC 86; SUCROSE; TRAMADOL; TYROSYLCYCLO[DEXTRO CYSTEINYLPHENYLALANYL DEXTRO PENICILLAMINE]; U 69493; UFP 512; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDICTION; ANHEDONIA; ASTROCYTE; AVERSION; CELL FATE; COMORBIDITY; DEPRESSION; FORCED SWIMMING TEST; GABAERGIC SYSTEM; HOPELESSNESS; HUMAN; KNOCKOUT MOUSE; LEARNED HELPLESSNESS; MAJOR DEPRESSION; MATERNAL DEPRIVATION; MEDIAN RAPHE NUCLEUS; MONOAMINERGIC SYSTEM; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NONHUMAN; OLIGODENDROGLIA; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REINFORCEMENT; REVIEW; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL LIFE; STRESS; STRIA TERMINALIS;

AFFECT; ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN CHEMISTRY; BRAIN-DERIVED NEUROTROPHIC FACTOR; COMORBIDITY; FEMALE; HUMANS; MALE; MATERNAL BEHAVIOR; MICE; MICE, KNOCKOUT; MODELS, NEUROLOGICAL; MOOD DISORDERS; NARCOTIC ANTAGONISTS; NERVE TISSUE PROTEINS; NEUROGENESIS; NEURONAL PLASTICITY; NEUROTRANSMITTER AGENTS; OPIOID PEPTIDES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, OPIOID; REWARD; SOCIAL BEHAVIOR; SUBSTANCE-RELATED DISORDERS;

EID: 84875273292     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.11.002     Document Type: Review

References (153)

1. Le Merrer J., et al. Reward processing by the opioid system in the brain. Physiol. Rev. 2009, 89:1379-1412.
2. Bodnar R.J. Endogenous opiates and behavior: 2010. Peptides 2011, 32:2522-2552.
3. Berrocoso E., et al. Opiates as antidepressants. Curr. Pharm. Des. 2009, 15:1612-1622.
4. Mueller T.I., et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am. J. Psychiatry 1999, 156:1000-1006.
5. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3:e442.
6. Tenore P.L. Psychotherapeutic benefits of opioid agonist therapy. J. Addict. Dis. 2008, 27:49-65.
7. Trivedi M.H., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
8. Machado-Vieira R., Zarate C.A. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress. Anxiety 2011, 28:267-281.
9. Gerra G., et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004, 75:37-45.
10. Hegadoren K.M., et al. The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides 2009, 43:341-353.
11. Gaveriaux-Ruff C., Kieffer B.L. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002, 36:62-71.
12. Nguyen A.T., et al. The rewarding action of acute cocaine is reduced in beta-endorphin deficient but not in mu opioid receptor knockout mice. Eur. J. Pharmacol. 2012, 686:50-54.
13. Nguyen A.T., et al. The role of mu opioid receptors in psychomotor stimulation and conditioned place preference induced by morphine-6-glucuronide. Eur. J. Pharmacol. 2012, 682:86-91.
14. Der-Avakian A., Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012, 35:68-77.
15. Contet C., et al. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 2004, 14:370-378.
16. Filliol D., et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 2000, 25:195-200.
17. Yoo J.H., et al. Altered emotional behaviors and the expression of 5-HT1A and M1 muscarinic receptors in μ-opioid receptor knockout mice. Synapse 2004, 54:72-82.
18. Pradhan A.A., et al. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol. Sci. 2011, 32:581-590.
19. Chefer V.I., Shippenberg T.S. Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology 2009, 34:887-898.
20. Le Merrer J., et al. Deletion of the delta opioid receptor gene impairs place conditioning but preserves morphine reinforcement. Biol. Psychiatry 2011, 69:700-703.
21. David V., et al. Brain regional Fos expression elicited by the activation of mu- but not delta-opioid receptors of the ventral tegmental area: evidence for an implication of the ventral thalamus in opiate reward. Neuropsychopharmacology 2008, 33:1746-1759.
22. Roberts A.J., et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol. Clin. Exp. Res. 2001, 25:1249-1256.
23. Berrendero F., et al. Influence of delta-opioid receptors in the behavioral effects of nicotine. Neuropsychopharmacology 2012, 37:2332-2344.
24. Konig M., et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 1996, 383:535-538.
25. Markou A., et al. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18:135-174.
26. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl.) 2010, 210:121-135.
27. Knoll A.T., Carlezon W.A. Dynorphin, stress, and depression. Brain Res. 2010, 1314:56-73.
28. Bruchas M.R., et al. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314:44-55.
29. Kastin A.J., et al. Enkephalin and other peptides reduce passiveness. Pharmacol. Biochem. Behav. 1978, 9:515-519.
30. Tejedor-Real P., et al. Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol. Psychiatry 1993, 34:100-107.
31. Tejedor-Real P., et al. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol. Biochem. Behav. 1995, 52:145-152.
32. Broom D.C., et al. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002, 26:744-755.
33. Broom D.C., et al. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl.) 2002, 164:42-48.
34. Javelot H., et al. Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J. Physiol. Pharmacol. 2010, 61:355-362.
35. Jutkiewicz E.M., et al. Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 2004, 309:173-181.
36. Jutkiewicz E.M., et al. Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(αR)-α-[(2S, 5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 2005, 315:414-422.
37. Jutkiewicz E.M., et al. Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology (Berl.) 2005, 182:588-596.
38. Jutkiewicz E.M., et al. Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav. Pharmacol. 2003, 14:509-516.
39. Jutkiewicz E.M., et al. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur. J. Pharmacol. 2006, 531:151-159.
40. Naidu P.S., et al. NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur. J. Pharmacol. 2007, 566:132-136.
41. Nieto M.M., et al. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 2005, 135:305-313.
42. Noble F., et al. Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours. Psychopharmacology (Berl.) 2008, 196:327-335.
43. Saitoh A., et al. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci. 2004, 95:374-380.
44. Saitoh A., et al. The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav. Brain Res. 2011, 223:271-279.
45. Saitoh A., et al. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(αR)-α-[(2S, 5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res. 2008, 1208:160-169.
46. Tejedor-Real P., et al. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur. J. Pharmacol. 1998, 354:1-7.
47. Torregrossa M.M., et al. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006, 1069:172-181.
48. 2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 2008, 29:93-103.
49. Yang Q.Z., et al. The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice. Neurosci. Lett. 2011, 489:131-135.
50. Berrocoso E., et al. Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int. J. Neuropsychopharmacol. 2013, 16:151-162.
51. Berrocoso E., Mico J.A. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int. J. Neuropsychopharmacol. 2009, 12:1033-1044.
52. Besson A., et al. Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats. Psychopharmacology (Berl.) 1996, 123:71-78.
53. Rojas-Corrales M.O., et al. Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci. 2002, 72:143-152.
54. Zhang H., et al. Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through δ- and μ-opioid receptors independent of antidepressant-like effects. Eur. J. Neurosci. 2006, 23:984-994.
55. Beardsley P.M., et al. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 2005, 183:118-126.
56. Mague S.D., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 2003, 305:323-330.
57. Shirayama Y., et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem. 2004, 90:1258-1268.
58. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 2010, 167:1305-1320.
59. Ribeiro S.C., et al. Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:1264-1280.
60. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
61. Svingos A.L., et al. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 2001, 42:185-192.
62. Newton S.S., et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 2002, 22:10883-10890.
63. Bertrand E., et al. Social interaction increases the extracellular levels of [Met]enkephalin in the nucleus accumbens of control but not of chronic mild stressed rats. Neuroscience 1997, 80:17-20.
64. Cordonnier L., et al. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 2005, 135:1-10.
65. Hipolito L., et al. Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens. Neuropharmacology 2008, 55:183-189.
66. Devoize J.L., et al. Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology (Berl.) 1984, 84:71-75.
67. Tao R., Auerbach S.B. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 1995, 68:553-561.
68. Fadda P., et al. Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. Synapse 2005, 56:29-38.
69. Tao R., Auerbach S.B. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J. Pharmacol. Exp. Ther. 2002, 303:704-710.
70. Jolas T., et al. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 2000, 95:433-443.
71. Anraku T., et al. Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test. Psychopharmacology (Berl.) 2001, 157:217-220.
72. Molina V.A., et al. Chronic variable stress or chronic morphine facilitates immobility in a forced swim test: reversal by naloxone. Psychopharmacology (Berl.) 1994, 114:433-440.
73. Grasing K., Ghosh S. Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal. Neuropharmacology 1998, 37:1007-1017.
74. Hodgson S.R., et al. Different affective response to opioid withdrawal in adolescent and adult mice. Life Sci. 2009, 84:52-60.
75. Goeldner C., et al. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol. Psychiatry 2011, 69:236-244.
76. 1A receptor function during withdrawal from chronic morphine. Eur. Neuropsychopharmacol. 2011, 21:835-840.
77. Rainer Q., et al. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol. Pharmacol. 2012, 81:106-112.
78. Zhao Z.Q., et al. Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14519-14524.
79. Tao R., Auerbach S.B. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J. Pharmacol. Exp. Ther. 2002, 303:549-556.
80. Land B.B., et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19168-19173.
81. Bruchas M.R., et al. Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011, 71:498-511.
82. Rossetti Z.L., et al. Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats: tolerance and withdrawal mechanisms. Brain Res. 1993, 609:316-320.
83. Delfs J.M., et al. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000, 403:430-434.
84. Harris G.C., Aston-Jones G. Activation in extended amygdala corresponds to altered hedonic processing during protracted morphine withdrawal. Behav. Brain Res. 2007, 176:251-258.
85. Hanson N.D., et al. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
86. Snyder J.S., et al. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461.
87. Robinson T.E., et al. Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats. Synapse 2002, 46:271-279.
88. Eisch A.J., Harburg G.C. Opiates, psychostimulants, and adult hippocampal neurogenesis: Insights for addiction and stem cell biology. Hippocampus 2006, 16:271-286.
89. Harburg G.C., et al. Knockout of the mu opioid receptor enhances the survival of adult-generated hippocampal granule cell neurons. Neuroscience 2007, 144:77-87.
90. Cominski T.P., et al. Loss of the mu opioid receptor on different genetic backgrounds leads to increased bromodeoxyuridine labeling in the dentate gyrus only after repeated injection. Neuroscience 2012, 206:49-59.
91. Dranovsky A., et al. Experience dictates stem cell fate in the adult hippocampus. Neuron 2011, 70:908-923.
92. Song P., Zhao Z.Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 2001, 39:281-286.
93. Persson A.I., et al. Mu- and delta-opioid receptor antagonists decrease proliferation and increase neurogenesis in cultures of rat adult hippocampal progenitors. Eur. J. Neurosci. 2003, 17:1159-1172.
94. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70:289-297.
95. Torregrossa M.M., et al. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 2004, 29:649-659.
96. Zhang H., et al. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-binaltorphimine: behavioral and BDNF mRNA expression studies. Eur. J. Pharmacol. 2007, 570:89-96.
97. Ansorge M.S., et al. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 2007, 7:8-17.
98. Bale T.L., et al. Early life programming and neurodevelopmental disorders. Biol. Psychiatry 2010, 68:314-319.
99. Traudt C.M., et al. Postnatal morphine administration alters hippocampal development in rats. J. Neurosci. Res. 2012, 90:307-314.
100. Klausz B., et al. Changes in adaptability following perinatal morphine exposure in juvenile and adult rats. Eur. J. Pharmacol. 2011, 654:166-172.
101. de Cubas M.M., Field T. Children of methadone-dependent women: developmental outcomes. Am. J. Orthopsychiatry 1993, 63:266-276.
102. Ornoy A., et al. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl. 1996, 20:385-396.
103. Meyer-Lindenberg A., Tost H. Neural mechanisms of social risk for psychiatric disorders. Nat. Neurosci. 2012, 15:663-668.
104. Stein D.J., et al. Opioids: from physical pain to the pain of social isolation. CNS Spectr. 2007, 12. 669-670, 672-674.
105. Eisenberger N.I. The pain of social disconnection: examining the shared neural underpinnings of physical and social pain. Nat. Rev. Neurosci. 2012, 13:421-434.
106. Panksepp J. Neuroscience. Feeling the pain of social loss. Science 2003, 302:237-239.
107. Kennedy B.C., et al. Social influences on morphine-conditioned place preference in adolescent BALB/cJ and C57BL/6J mice. Psychopharmacology (Berl.) 2012, 219:923-932.
108. Komatsu H., et al. Decreased response to social defeat stress in mu-opioid-receptor knockout mice. Pharmacol. Biochem. Behav. 2011, 99:676-682.
109. Mague S.D., Blendy J.A. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 2010, 108:172-182.
110. Troisi A., et al. Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. Soc. Neurosci. 2011, 6:88-97.
111. Way B.M., et al. Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15079-15084.
112. McLaughlin J.P., et al. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 2006, 31:1241-1248.
113. Resendez S.L., et al. κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance. J. Neurosci. 2012, 32:6771-6784.
114. Niesink R.J., et al. Social behavior of juvenile rats after in utero exposure to morphine: dose-time-effect relationship. Neuropharmacology 1999, 38:1207-1223.
115. Hol T., et al. Prenatal exposure to morphine affects juvenile play behavior and adult social behavior in rats. Pharmacol. Biochem. Behav. 1996, 55:615-618.
116. Bowlby J. Attachment and loss: retrospect and prospect. Am. J. Orthopsychiatry 1982, 52:664-678.
117. Moles A., et al. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 2004, 304:1983-1986.
118. Kalin N.H., Shelton S.E. Defensive behaviors in infant rhesus monkeys: environmental cues and neurochemical regulation. Science 1989, 243:1718-1721.
119. Barr C.S., et al. Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5277-5281.
120. Copeland W.E., et al. Child mu-opioid receptor gene variant influences parent-child relations. Neuropsychopharmacology 2011, 36:1165-1170.
121. Kalinichev M., et al. Early neonatal experience of Long-Evans rats results in long-lasting changes in morphine tolerance and dependence. Psychopharmacology (Berl.) 2001, 157:305-312.
122. Kalinichev M., et al. Repeated neonatal maternal separation alters morphine-induced antinociception in male rats. Brain Res. Bull. 2001, 54:649-654.
123. Weaver S.A., et al. Maternal separation leads to persistent reductions in pain sensitivity in female rats. J. Pain 2007, 8:962-969.
124. Liu D., et al. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 1997, 277:1659-1662.
125. Lewis J.M. For better or worse: interpersonal relationships and individual outcome. Am. J. Psychiatry 1998, 155:582-589.
126. Ladd G.W. Peer relationships and social competence during early and middle childhood. Annu. Rev. Psychol. 1999, 50:333-359.
127. Panksepp J.B., Lahvis G.P. Social reward among juvenile mice. Genes Brain Behav. 2007, 6:661-671.
128. Trezza V., et al. The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol. Sci. 2010, 31:463-469.
129. Van den Berg C.L., et al. Morphine treatment during juvenile isolation increases social activity and opioid peptides release in the adult rat. Brain Res. 1999, 830:16-23.
130. Vanderschuren L.J., et al. Mu- and kappa-opioid receptor-mediated opioid effects on social play in juvenile rats. Eur. J. Pharmacol. 1995, 276:257-266.
131. Kessler R.C. The epidemiology of dual diagnosis. Biol. Psychiatry 2004, 56:730-737.
132. Paterson N.E., Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox. Res. 2007, 11:1-32.
133. Nunes E.V., et al. Treatment of depression in patients with opiate dependence. Biol. Psychiatry 2004, 56:793-802.
134. Lutfy K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr. Neuropharmacol. 2004, 2:395-402.
135. Escriba P.V., et al. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004, 29:1512-1521.
136. Gabilondo A.M., et al. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 1995, 682:245-250.
137. Gross-Isseroff R., et al. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res. 1990, 530:312-316.
138. Zubieta J.K., et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch. Gen. Psychiatry 2003, 60:1145-1153.
139. Kennedy S.E., et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch. Gen. Psychiatry 2006, 63:1199-1208.
140. Shippenberg T.S., et al. Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction. CNS Neurol. Disord. Drug Targets 2008, 7:442-453.
141. Tejeda H.A., et al. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell. Mol. Life Sci. 2012, 69:857-896.
142. Manglik A., et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 2012, 485:321-326.
143. Granier S., et al. Structure of the delta-opioid receptor bound to naltrindole. Nature 2012, 485:400-404.
144. Wu H., et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485:327-332.
145. Haga K., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
146. He L., et al. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002, 108:271-282.
147. Shukla A.K., et al. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 2011, 36:457-469.
148. Pradhan A.A., et al. Ligand-directed signaling within the opioid receptor family. Br. J. Pharmacol. 2012, 167:960-969.
149. Tassin J.P. Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse. Biochem. Pharmacol. 2008, 75:85-97.
150. Sharp B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav. Immun. 2006, 20:9-14.
151. Sery O., et al. A118G polymorphism of OPRM1 gene is associated with schizophrenia. J. Mol. Neurosci. 2010, 41:219-222.
152. Prossin A.R., et al. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am. J. Psychiatry 2010, 167:925-933.
153. Olmstead M.C., et al. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS ONE 2009, 4:e4410.